A kidney anemia drug lowered hospitalization rates 10% versus standard treatment in dialysis patients.
Akebia Therapeutics (AKBA) announced that vadadustat, its kidney anemia drug, reduced hospitalization rates by 10% compared to standard treatment in dialysis patients, according to the VOICE trial presented at ASN Kidney Week 2026. The trial, sponsored by U.S. Renal Care, showed fewer serious adverse events and better hemoglobin control with vadadustat. Vafseo, the brand name for vadadustat, was approved by the FDA in March 2024 for anemia treatment in dialysis patients.
How this was made
The 30-second read
Why it matters
The data provides the first robust efficacy signal for vadadustat, positioning it as a potential new standard of care.
Market read
Positive trial data could lift AKBA stock and affect the broader anemia‑treatment sector.
What to watch
Long‑term safety signals and reimbursement decisions could limit commercial upside despite trial results.
Background
Akebia Therapeutics (NASDAQ: AKBA) announced results from its VOICE trial of vadadustat, an oral HIF‑PHI for anemia in dialysis patients.
Ticker impact
Akebia Therapeutics reported Phase 3 VOICE trial results showing a 10% reduction in hospitalization rates versus ESA.
likely upside as investors price in lower hospitalization risk and potential market share gain.
The trial demonstrates statistically significant clinical benefit with no mortality difference, a first‑report disclosure for a mid‑cap biotech, which typically moves the stock on the day of release.
Market effects
May strengthen the HIF‑PHI class outlook and increase investor interest in oral anemia therapies.
U.S. dialysis provider market could see competitive pressure as a new oral option gains traction.
Potential to influence global anemia drug pipelines, especially in markets without oral HIF‑PHI competitors.
Counterpoint
If hospitalization reduction does not translate into cost savings for payors, the market may overprice the benefit.
Key entities
- companyAkebia Therapeutics
Biopharma developing kidney disease therapies, listed on Nasdaq.
- companyU.S. Renal Care
Largest privately held dialysis provider, trial sponsor.
